Although bevacizumab initially shows high response rates in gliomas and other tumours, therapy resistance usually develops later. Because anti-angiogenic agents are supposed to induce hypoxia, we asked whether rendering glioma cells
independent of oxidative phosphorylation modulates their sensitivity against hypoxia and bevacizumab. LNT-229 glioma cells without functional mitochondria (rho 0 ) and control (rho + ) cells were generated. LNT-229 rho 0 -cells displayed reduced expression of oxidative phosphorylation-related genes and diminished oxygen consumption. Conversely, glycolysis was up-regulated in these cells, as shown by increased lactate production and stronger expression of glucose transporter-1 and lactate dehydrogenase-A. However, hypoxia-induced cell death in vitro was nearly completely abolished in the LNT-229 rho 0 -cells, these cells were more sensitive towards glucose restriction and the treatment with the glycolysis inhibitor 2-deoxy-D-glucose. In an orthotopic mouse xenograft experiment, bevacizumab induced hypoxia as reflected by elevated Hypoxia-inducible factor 1-alpha staining in both, rho + -and rho 0 -tumours. However, it prolonged survival only in the mice bearing rho + -tumours (74 days vs. 105 days, p = 0.024 log-rank test) and had no effect on survival in mice carrying LNT-229 rho 0 -tumours (75 days vs. 70 days, p = 0.52 logrank test). Interestingly, inhibition of glycolysis in vivo with 2-deoxy-D-glucose re-established sensitivity of rho 0 -tumours against bevacizumab (98 days vs. 80 days, p = 0.0001). In summary, ablation of oxidative phosphorylation in glioma cells leads to a more glycolytic and hypoxia-resistant phenotype and is sufficient to induce bevacizumab-refractory tumours. These results add to increasing evidence that a switch towards glycolysis is one mechanism how tumour cells may evade anti-angiogenic treatments and suggest anti-glycolytic strategies as promising approaches to overcome bevacizumab resistance. Keywords: bevacizumab, glioma, glycolysis, hypoxia resistance, oxidative phosphorylation. Targeting angiogenesis is a promising therapeutic approach against cancer. Bevacizumab, a humanized antibody against vascular endothelial growth factor (VEGF), is widely used against different tumours including malignant glioma (Jain 2014) . In glioma, high response rates (Friedman et al. 2009 ), prolonged progression-free survival (Friedman et al. 2009; Chinot et al. 2014; Gilbert et al. 2014 ) and sustained magnetic resonance imaging (MRI) alterations (Bahr et al. 2011) indicate that bevacizumab has profound biological effects on malignant glioma. However, therapy resistance almost inevitably evolves, and bevacizumab-resistant glioma are highly refractory against conventional rescue therapies (Kreisl et al. 2009; Rahman et al. 2014) . How bevacizumab exerts its effects on tumours is incompletely understood. There is increasing evidence that anti-angiogenic treatment induces hypoxia in solid tumours as glioma (Baumgarten et al. 2011 ). This assumption is based on the results of mouse xenograft models, where accumulation of Hypoxia-inducible factor 1-alpha (HIF-1a) and carboanhydrase IX could be observed in bevacizumabtreated glioma (de Groot et al. 2010; Favaro et al. 2012; Jahangiri et al. 2013) . Our own results further support this hypothesis, showing stroke-like lesions in MRI in bevacizumab-treated glioma and histopathological findings indicative of hypoxia and atypical necrosis (Rieger et al. 2010) .
Therefore, two types of resistance against bevacizumab can be postulated: tumours could escape therapy by inducing VEGF-independent angiogenesis (Bergers and Hanahan 2008) , or tumour cells could adapt to survive under hypoxia and starvation condition. Based on the MRI appearance, two major groups of bevacizumab-resistant glioma were recently described (DeLay et al. 2012) . One was called nonenhancing resistant glioblastoma (NBRG) because of its low proportion of gadolinium enhancement of the fluidattenuated inversion recovery bright volume, whereas the other group, called enhancing bevacizumab-resistant glioblastoma, exhibited a higher percentage of gadolinium enhancement. The enhancing bevacizumab-resistant glioblastoma showed higher vessel density and less hypoxia, whereas non-enhancing resistant glioblastomas were characterized by a low vascularity and a high extent of hypoxia, indicative of hypoxia resistance in these tumours.
How exactly adaptation to hypoxia occurs in tumours treated with anti-angiogenic therapies is unclear. A persistent loss of mitochondrial protein complex I in bevacizumab resistant-xenografts of a colon carcinoma cell line was reported (Xu et al. 2013) . Furthermore, mitochondria that were isolated from human gliomas were functionally disturbed after in vitro bevacizumab exposure (Nanegrungsunk et al. 2016) . Recently, in ovarian and breast cancer cells, it was shown that bevacizumab-resistant cells showed increased glycolysis (Curtarello et al. 2015) . Accordingly, in glioma cells, Keunen et al. demonstrated increased expression of HIF-1a and accumulation of lactate in a mouse glioma model after treatment with bevacizumab (Keunen et al. 2011) . The authors recently extended these findings by demonstrating that bevacizumab leads to a metabolic switch towards anaerobic glycolysis (Fack et al. 2015) . While these results suggest that bevacizumab-resistant tumours develop a more glycolytic phenotype, it is still unclear whether these metabolic alterations are causally responsible for resistance against anti-angiogenic treatments or an epiphenomenal metabolic adaptation. To examine whether inducing a glycolytic, oxidative phosphorylationindependent phenotype is sufficient to cause bevacizumab resistance, we generated glioma cells with a defective respiratory chain (rho 0 -cells). These rho 0 -cells are expected to be less dependent on oxygen supply. We investigated the response of these cells against hypoxia in vitro and against bevacizumab and 2-deoxy-D-glucose (2DG) in a mouse xenograft model.
Material and Methods

Cell lines
The human glioblastoma cell line LNT229 (ATCC Cat# CRL-2611, RRID:CVCL_0393) was kindly provided by Monika Hegi (Labor for tumor biology and genetics, Lausanne, Switzerland). The cell line derived from the LN229 cells. The LN229 cells harbor a p53 mutation (Wischhusen et al. 2003) while LNT229 carry the wildtype gene (Berger et al. 2010) . The cell line has been used in our laboratory for several studies (recently by Thiepold et al. 2017 ). The LNT229 cell line is not listed as a commonly misidentified cell line (International Cell Line Authentication Committee). The cells were last authenticated just before the first animal experiment in 04/2013 (by Multiplexion, Mannheim, Germany). Cells were cultured in standard culture medium (Dulbecco's modified Eagle's medium, PAA, Coelbe, Germany) containing 10% fetal calf serum (FCS), lglutamine, 4500 mg/L glucose, 110 mg/L sodium pyruvate, 100 IU/mL penicillin, and 100 mg/mL streptomycin. To generate LNT229 rho 0 -cells and corresponding control cells (LNT229 rho + ), LNT229-cells were cultured for >2 months in uridine (50 lg/mL) in the absence (LNT229 rho + -cells) or presence (LNT229 rho 0 -cells) of ethidium bromide (200 ng/mL) as described previously (Miller et al. 1996) . In experiments requiring defined glucose conditions, Dulbecco 0 s modified Eagle 0 s glucose and pyruvate-free medium was used without FCS. A quantity of 100 lg/mL pyruvate and 50 lg/ mL uridine were added, glucose levels were adjusted as required. Cells were seeded at a density of 5. 
Expression of the housekeeping gene SDHA (succinate dehydrogenase complex, subunit A) was used to analyse Cycle threshold (Ct) values with the 2 ÀDDCT method as described before (Vandesompele et al. 2002) .
Mitotracker staining
Mitotracker red and green staining was carried out as described in the user's manual (Invitrogen). Briefly, cells were seeded in a 24-well plate and kept 24 h under standard conditions. Afterwards, cells were washed with phosphate buffered saline (PBS) and stained for 15 min with 25 nM mitotracker green or red in standard medium. After the staining, the medium was removed and exchanged with standard medium. Cells were immediately observed under the fluorescence microscope (Biozero, Keyence, Osaka, Japan).
Tetramethylrhodamine (TMRM) flow cytometry
Cells were seeded in a 24-well plate and incubated for 24 h under standard conditions. Afterwards, they were washed in PBS and incubated with 25 nM TMRM in medium containing 5mM glucose for 45 min at 37°C and normoxia (5% O 2 ). Flow cytometry was immediately performed to evaluate the membrane potential.
Oxygen consumption
Oxygen consumption was measured using the ABL-80 FLEX Blood Gas Analyser (Radiometer, Willich, Germany) as previously described (Wanka et al. 2012) .
Reactive oxygen species (ROS) analysis
Cells were seeded in 24-well plates and incubated for 24 h under standard conditions. Thereafter, cells were washed in PBS and incubated for 20 h in medium containing 5 mM glucose. Cells were then washed twice with PBS, incubated 20 min. at normoxia (5% O 2 ) at 37°C with 10 lM H 2 DCFDA (Invitrogen), washed with PBS and collected for flow cytometry analysis. DCF signal was analysed by BD Canto II.
Measurement of lactate production
Cells were treated with medium containing 25 mM glucose and incubated at normoxia or hypoxia (5% or 0.1% O 2 ) for 3 days. Cellfree supernatant was collected and lactate concentrations were measured at baseline and after the experiment using the biochemistry analyser Hitachi 917. Lactate production was calculated by subtracting values at 72 h from baseline values, and these values were normalised to protein concentrations measured at the end of the experiment.
Crystal violet assay to assess cell density Cell density under glucose restriction and 2-DG treatment was assessed by crystal violet staining. Cells were seeded in 96-well plates with a density of 5000/well in Dulbecco's modified Eagle's medium and kept for 24 h under standard conditions to allow the cells to attach. A crystal violet staining was performed to ensure equal cell densities. Subsequently the standard medium was substituted with medium adjusted to 5, 2 or 1 mM glucose and cells were incubated for 12 h under normoxia (5% O 2 ) with or without 5 mM 2DG. Thereafter, a crystal violet staining was performed to evaluate cell densities (Kueng et al. 1989) . Results were expressed as percent of cell densities under 5 mM glucose without 2DG.
Hypoxia-induced cell death
Hypoxia induced cell death was assessed by propidium iodide (PI)-flow cytometry. Cells were seated in 24-well plates and incubated for 24 h in under standard conditions. Afterwards, cells were washed in PBS and kept in medium containing 5mM glucose for 24 h under normoxia or hypoxia (5% or 0.1% O 2 ). 0.1% oxygen was induced using Gas Pak pouches for anaerobic culture (BectonDickinson, Heidelberg, Germany). This was followed by a staining with 5 lg/mL PI and subsequent flow cytometry analysis.
Carboxyfluorescein succinimidyl ester (CFSE) staining
For co-culture of the cell lines, LNT229 rho 0 -cells were stained with carboxyfluorescein succinimidyl ester (BioLegend, SanDiego, CA, USA). Cells were washed gently in PBS, stained for 10 min. in PBS containing CFSE (10 lM), and thereafter incubated for 10 min in medium containing 10% FCS. Subsequently, the cells were washed, mixed in equal amounts with unstained LNT229 rho + -cells, and 150 000 cells/well were seeded in 24-well plates. After 24 h incubation under standard conditions a flow cytometry analysis was performed to assess baseline proportions of LNT229 rho 0 and rho + cells. Afterwards, the co-cultures were incubated at normoxia or hypoxia (5% or 0.1% O 2 ) in medium containing 5mM glucose for 24 h and again stained and unstained cells were counted by flow cytometry analysis. The proportion of cells after 24 h at 5% or 0.1% O 2 was calculated relative to baseline proportions.
Animal care and tumour transplantation
Female inbred athymic nude mice (HSD: Athymic Nude-Foxn1nu, Harlan, Indianapolis, USA) were housed in groups of 4 animals per cage in a specific pathogen-free facility with a 12-h light/12-h dark cycle and given free access to food and water. All experimental procedures were approved by the local animal ethics committee (regional board Darmstadt F145/02) and conducted according to the guidelines for ethical use of animals in the Declaration of Helsinki.
A scheme of the experimental procedure is shown in Fig. 1 . At the age of 6 weeks, 100 000 LNT229 rho 0 -or rho + -cells were injected intracranial, 2 mm right and 1 mm anterior to bregma suture; as described before (Lee et al. 2012) . No statistical method was used to predetermine the sample size. After implantation, animals were placed into cages by a researcher blinded for the further treatment. Ten days after implantation PBS or bevacizumab (1 mg/kg) treatment was started with intraperitoneal injections twice a week (A). Animals that received 2DG treatment were injected intraperitoneal at day 7-9 with 500 mg/kg 2DG. Thereafter, 2DG or 2DG with bevacizumab was administered twice a week (B). Animals were monitored for health and behaviour three times weekly. The study was not preregistered but the primary endpoint was defined before the start and was not changed during the experiment. The primary endpoint was defined as symptomatic animals (20% weight loss, or neurological symptoms as paresis or epileptic seizures). The researcher that observed the animals was blinded for the treatment conditions. When the endpoint was reached, the animals were scarified immediately and the tumour tissue was extracted and put in paraformaldehyde for histology. One animal in the rho 0 BEV group of the first experiment did not develop any tumour, one animal in the rho 0 PBS group of the first experiment died because of anaesthesia, one animal in the rho 0 BEV group of the second experiment was sacrificed because of systemic tumour spread; these animals were excluded from the statistics. Subcutaneous tumour xenografts were implanted to observe growth kinetics and for RNA retrieval. 4000 000 cells were injected subcutaneously to the left and right side of the animals. Volume of subcutaneously implanted LNT229 rho + -and rho 0 -tumours was quantified at different time points by a caliper (height*height*width/2). After 40 days, three tumours per group were extracted and immediately taken into liquid nitrogen for q-PCR analysis. 500 mg/kg 2DG intraperitoneal at day 7-9, the others received PBS. From day 10 until the first symptoms, 2DG injections were continued or 2DG with bevacizumab (1 mg/kg), respectively, bevacizumab alone administered twice a week. One animal in the rho 0 BEV group was excluded from the statistics because of systemic tumour spread at day 114 (*3).
Histology and immunohistochemistry
Brains were fixed in 4% paraformaldehyde in PBS and embedded in paraffin. Coronal sections (3 lm) were cut using a microtome and hematoxylin eosin stained according to standard protocols. Immunohistochemical preparations were performed using a Discovery XT automated staining module (Ventana, Tucson, AZ, USA) and standard protocols. As primary antibodies we used monoclonal rabbit anti-human lactate dehydrogenase-A (LDH-A) (dilution: 1 : 100; Cell Signalling Technology, Cambridge, UK, Cat# 3582S RRID:AB_2066887), polyclonal rabbit anti-human HIF1a (dilution: 1 : 100, Novus Biologicals, Littleton, CO, USA, Cat# NB100-134 RRID:AB_350071), and polyclonal rabbit anti-mouse glial fibrillary acidic protein (dilution: 1 : 5000, Dako, Hamburg, Germany, Cat# Z0334, RRID:AB_10013382)
Blinding Blinding was performed for the animal experiments as described above, for all other experiments no blinding was performed.
Statistics Shapiro-Wilk test was performed as assessment of normality for all experiments, except for survival analysis. All except oxygen consumption were normally distributed (defined as p > 0.05) and were analysed for significance using unpaired student 0 s t-test.
Mann-Whitney-U Test was used to analyse oxygen consumption. All numerical data were expressed as mean AE SEM. Survival analysis was done with Kaplan-Meier statistics and log-rank (mantel-cox) test. No test for outliners was conducted. No randomization methods were employed. Differences were considered significant at a p-value of < 0.05. Levels of significance were indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Results
LNT-229 rho 0 -cells are characterized by reduced oxygen consumption, increased glycolysis, and sensitivity towards 2DG To deplete mitochondrial DNA in glioblastoma cells, the glioblastoma cell line LNT-229 was cultured for 2 months in the presence of ethidium bromide and uridine (LNT-229 rho 0 -cells), (Miller et al. 1996) . The expression of mitochondrial encoded genes of the respiratory chain complex was strongly suppressed in the LNT-229 rho 0 -cells (Fig. 1a) . In contrast, the expression of mitochondrial glutaminase 2 (GLS2), which is nuclear encoded was not affected by ethidium bromide treatment (Fig. 2a) .
Furthermore, flow cytometry of TMRM stained cells and microscopic observation of CMXROS red staining revealed a reduction in mitochondrial membrane potential in LNT-229 rho 0 -cells, while microscopic observation of mitotracker green staining was comparable in rho 0 -and rho + -cells (Fig. 2b-d) . Mitotracker green stains free thiol groups of cystein residues belonging to mitochondrial proteins independent of the membrane potential and has been used to relate to mitochondrial mass (Agnello et al. 2008; Cottet-Rousselle et al. 2011) . As expected, the disturbed mitochondrial function in the LNT-229 rho 0 -cells was reflected by nearly complete suppression of oxygen consumption and lower reactive oxygen species levels ( Fig. 2e-g ).
In addition, these cells showed a more glycolytic phenotype with a higher lactate production (Fig. 3a) . Furthermore, the expression of glucose transporter-1 and LDH-A was elevated in the LNT-229 rho 0 -cells, indicating a more glycolytic phenotype (Fig 3b and c) . In addition, we tested whether LNT-229 rho 0 -cells were more susceptible towards glucose restriction and administration of 2DG, a competitive inhibitor of glycolysis. Cell growth inhibition under low glucose concentrations (1 mM) was aggravated in LNT-229 rho 0 -cells, suggesting a higher glucose consumption of this cells compared to LNT-229 rho + -cells. Interestingly, cell growth inhibition caused by 2DG was pronounced in rho 0 -compared to rho + -cells, while the combination of glucose restriction (1 mM) and 2DG was most effective (Fig. 3d) .
LNT-229 rho 0 -cells are resistant against hypoxia-induced cell death We subsequently analysed whether adaptation to suppressed oxidative phosphorylation in LNT-229 rho 0 -cells was associated to resistance against hypoxia. As shown in Fig. 4a (Fig. 4b) . Together, these results suggest that LNT-229 rho 0 -cells are resistant against hypoxia-induced cell death, providing these cells with a selective growth advantage under hypoxic conditions. Rho 0 -tumours are resistant against bevacizumab Since suppression of oxidative phosphorylation caused resistance against hypoxia in vitro, we asked whether LNT-229 rho 0 -tumours would be resistant to bevacizumab treatment in vivo. The expression of VEGF in the two cell lines was examined to analyse whether response to bevacizumab might be affected by different VEGF expression levels. No significant difference of VEGF expression on the mRNA level was observable between the two cell lines or subcutaneous xenografts (Fig. S1a) . We also examined whether tumour growth rate was different between subcutaneous LNT-229 rho + -and rho 0 -tumour xenografts, and did not find a significant difference (Fig. S1b) . To confirm in vivo persistence of the LNT-229 rho 0 -phenotype, the expression of respiratory chain proteins was quantified via PCR in LNT-229 rho 0 -and LNT-229 rho + -subcutaneous xenografts. The tumours formed from LNT-229 rho 0 -cells had a persistently decreased expression of oxidative phosphorylation-related genes compared to LNT-229 rho + -tumours (Fig. S1c) . Like the in vitro results, LDH-A expression was increased in rho 0 -compared to rho + -tumours in orthotopic xenografts (Fig. 5a ), indicating that LNT-229 rho 0 -tumours retained the metabolic phenotype in vivo. Finally, sensitivity of LNT-229 rho 0 -and rho + -tumours against bevacizumab was analysed.
While bevacizumab prolonged survival of mice bearing intracranial LNT-229 rho + -tumours (74 days vs. 105 days, p = 0.024 log-rank test), it had no effect on survival in mice carrying LNT-229 rho 0 -tumours (75 days vs. 70 days, p = 0.52 log-rank test) (Fig. 5b) . The histological analysis of untreated rho + -or rho 0 -tumours did not reveal considerable differences (Fig. 5c) . Bevacizumab induced hypoxia in rho + -as well as rho 0 -tumours, as displayed by an increase in HIF-1a accumulation and translocation to the cell nucleus after bevacizumab treatment (Fig. 5d ). No differences in the extent of necrotic foci were seen, and glial fibrillary acidic protein expression in residual murine brain tissues was similar showing increased immunoreactivity in close vicinity to the tumour border (data not shown). 2DG restores sensitivity of rho 0 -tumours against bevacizumab As LNT-229 rho 0 -cells were glucose-addicted and hypersensitive to 2DG in vitro, we asked whether 2DG would be able to rescue their resistance towards bevacizumab in vivo. Indeed, whereas neither treatment with 2DG (81 days vs. 80 days, p = 0.85) nor bevacizumab alone (81 days vs. 84 days, p = 0.13) improved the median survival compared to PBS, the combination of bevacizumab and 2DG showed a synergistic effect and prolonged the median survival by 22% compared to the PBS treated group (98 days vs. 80 days, p = 0.0001) (Fig. 5e) . No relevant differences in tumour morphology were observed between 2DG-treated rho 0 -cells as compared to their counterparts with additional bevacizumab treatment (Fig. 5f ).
Discussion
Understanding mechanisms of resistance against antiangiogenic therapies is of great interest because in gliomas, antiangiogenic drugs such as bevacizumab and cediranib do not result in sustained benefit and bevacizumab-resistant tumours are highly refractory to conventional therapies. Considering that these agents induce vessel rarefication (Baumgarten et al. 2011 ) and hypoxia (Xu et al. 2015) , it appears plausible that therapy resistance involves adaptation of tumour cells to hypoxic conditions. A possible major mechanism of resistance against hypoxia is that tumour cells undergo a metabolic switch from oxidative phosphorylation towards glycolysis. Indeed, Fack et al. (2015) recently showed that treatment with bevacizumab led to a more glycolytic phenotype in glioma xenograft tumours as reflected by an increase in glucose flux and lactate production. Similarly, in ovarian cancer xenografts, bevacizumab led to the emergence of cancer cells showing reduced oxidative phosphorylation and increased glucose utilization and lactate production (Curtarello et al. 2015) . The importance of increased glycolysis as a mediator of bevacizumabresistance is suggested by the finding that, in colorectal cancer, higher expression of glycolytic genes was associated with a worse prognosis in patients treated with bevacizumab and chemotherapy (Graziano et al. 2016) . Together, these results indicate that tumour cells undergo a metabolic switch towards glycolysis during bevacizumab therapy. As it is likely that glycolysis is enhanced under hypoxic conditions, it remained unclear if increased glycolysis is a prerequisite to bevacizumab resistance or an epiphenomenon as a result of the therapy-induced hypoxia. We now demonstrate that suppression of oxidative phosphorylation in rho 0 -cells accompanied by enforced glycolysis is sufficient to induce resistance against bevacizumab (Fig. 5) . Together, these observations demonstrate that the recent findings of a metabolic switch towards glycolysis in bevacizumab-treated tumours are indeed causative to resistance against antiangiogenic therapies. How this metabolic switch exactly occurs remains unclear but might be a consequence of a selective pressure on oxic tumour cells.
As rho 0 -cells are highly resistant against hypoxic conditions (Fig. 4) , these results strengthen the assumption that bevacizumab impairs tumour growth at least partly by induction of hypoxia. Conversely, treatment with anti-angiogenic agents would lead to a selection pressure favouring the survival of glycolytic and hypoxia-resistant tumour cells.
The increased dependency of these tumours on glycolysis suggests that targeting glucose metabolism is a promising strategy to circumvent bevacizumab-resistance. Indeed, while 2DG alone did not affect tumour growth, the combination of bevacizumab with 2DG was effective in the treatment of bevacizumab resistant LNT-229 rho 0 -tumours (Fig. 5) . In vitro, the effect of 2DG on cell proliferation was dependent on the ratio between glucose and 2DG, and the combination of glucose restriction together with 2DG treatment was most effective to inhibit proliferation of LNT-229-rho 0 -cells (Fig. 3d) . It could therefore be speculated that in 2DG-alone treated tumours, blood vessels and glucose supply were not decreased, and that persistent high glucose levels in the tumours result in antagonism of the growth-inhibitory effects of 2DG that are sufficient even for the higher glucose needs of rho 0 -cells. Treatment with bevacizumab might cause a shortage of glucose in the tumours by reducing blood flow as well as vessel permeability and increasing glucose consumption (Fack et al. 2015) . Because 2DG accumulates in the tumour cells (Pelicano et al. 2006) , 2DG levels in tumours might be less affected by bevacizumab compared to glucose levels, raising the 2DG to glucose ratio above the threshold necessary for growth inhibition.
Together, our results demonstrate that increased glycolysis and resistance towards hypoxia are sufficient to induce a bevacizumab-resistant phenotype in an experimental glioma model. The assumption that increasing glycolysis is a mechanism of resistance against antiangiogenic therapies is supported by the finding that glucose restriction by a ketogenic diet increased the activity of bevacizumab in a mouse xenograft model (Rieger et al. 2014) . Inhibiting glucose metabolism by either glycolysis inhibitors or glucose restriction might therefore be a promising strategy to improve the efficacy of antiangiogenic therapies.
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